JavaScript is disabled in your browser. Please enable JavaScript to view this website.

Why Biomarkers Matter Now

From Discovery to Clinical-Ready Biomarkers

For years, biomarker development followed a linear model: one biomarker, one assay, one decision. Today, diseases are more complex, requiring integration of genomics, transcriptomics, proteomics, metabolomics, imaging and clinical data to understand disease, identify therapeutic signals and stratify patients. Multi-omics has evolved from a specialized research approach into a critical component of translational and clinical research workflows. The current challenge lies in producing insights that are both reproducible and actionable.

Biomarker-Driven Research: Closing the Translation Gap

Despite major advances in technology, many biomarker programs continue to face challenges with:

  • Fragmented workflows and disconnected datasets
  • Inconsistent assay performance across sites
  • Limited scalability of sample and data workflows
  • Difficulty connecting biological findings to clinical outcomes
  • Regulatory and traceability requirements for clinical use

Researchers aim for deeper biological insights, robust assays, scalable workflows and a clear path from biomarker discovery to clinical application.

bio-marker-ebook

Connected Biomarker Workflows: From Discovery to Translation

Biomarker development drives precision medicine, yet fragmented data, complex workflows and disconnected insights often slow progress. This ebook explores how the life sciences companies of Danaher enable AI-powered biomarker workflows, integrating sample prep, automation, analysis and data management to drive faster, more confident decisions.

Download the eBook

full-rule-line-padding-black

Connecting Every Step from Sample to Clinical Insight

The life sciences companies of Danaher connect technologies spanning sample preparation, automation, analysis, imaging, mass spectrometry and data and AI management to form a seamless sample-to-insight workflow. This interconnected system allows researchers to progress smoothly from discovery and validation to patient stratification and clinical readiness, eliminating the need to manage separate platforms.

timeline-biomarker

Deeper Biological Insight

10x image

We see a way to increase confidence in biomarker discovery and validation with up to 10x greater sensitivity and quantitative data that scales

SCIEX | ZenoTOF 8600 system

Reveal Deeper Biological Insights Across Modalities

Integrated multi-omics, spatial biology and phenotypic analysis can uncover molecular mechanisms, biological pathways and patient heterogeneity that traditional workflows might miss. Researchers require technologies able to link genomic, proteomic, metabolomic, imaging and functional data to form a more comprehensive biological understanding.

Learn More

Blank 80x80

Reproducibility at Scale

80% more

We see a way to improve the recovery and consistency of your biotherapeutic sample by more than 80%, significantly accelerating the drug development process

Phenomenex | Biozen™ LC Columns

Improve Reproducibility Across Every Study

Biomarker programs frequently fail not due to biological factors, but because workflows are not consistently reproducible across different operators, studies or sites. Implementing automation and standardized sample preparation methods can minimize variability, boost throughput and enhance confidence in results. As biomarker initiatives advance toward translational and clinical uses, ensuring reproducibility becomes even more critical.

Learn More

Connect Data Across Modalities

20 biomarker

We see a way to design smarter clinical trials to improve the success rate by 20%

Genedata | Genedata Profiler

Transform Data Silos into Decision-Ready Insights

The most valuable biomarker insights often come from combining molecular, phenotypic, imaging and clinical data. However, many organizations face challenges due to fragmented datasets, incompatible formats and the time-consuming process of data integration. Researchers require a reliable data foundation capable of integrating various datasets while ensuring traceability, governance and regulatory compliance.

Learn More

full-rule-line-padding-black

Resources

scaling-oncology-ngs-biomarker-ready-translational-research

Webinar

Scaling Oncology NGS for Biomarker-Ready Translational Research

Translational oncology teams need reliable NGS workflows that scale with increasing study volumes and inform future decisions. In this webinar, experts from IDT and Beckman Coulter will explore:

  • How manual library preparation increases time and variability and makes standardization difficult
  • How Archer FUSIONPlex-HT and VARIANTPlex-HT assays automated on the Biomek i3 can address these challenges
  • A walkaway workflow that reduces hands-on time while maintaining library quality

Learn More

ai-powered-biomarker-discovery

Webinar

AI-Powered Biomarker Discovery: From Screening to Translational Insights

Biomarker discovery is crucial for precision medicine, but complex assays, workflow scaling and translating results into insights can slow progress. This webinar shows how integrated, AI-powered solutions from Leica Microsystems and Molecular Devices can help researchers:

  • Reduce delays and improve reproducibility across biomarker workflows
  • Accelerate phenotypic screening with advanced imaging and analytics
  • Generate insights with stronger translational relevance

Learn More

innovative-ai-software-solutions-driving-biomarker

Webinar

Innovative AI Software Solutions Driving Biomarker Research Efficiency

Biomarker discovery and validation are crucial for personalized medicine and improved treatments, but high-throughput assays and image analyses can hinder efficient insight generation. Join this webinar to learn how Genedata Profiler and Leica’s Aivia AI software assist researchers.

  • Simplify complex high-throughput and image-based workflows
  • Shorten time to insights
  • Advance biomarker research with integrated data and AI-powered analysis

Learn More

cell-gene-therapy-biomarkers

Webinar

Cell and Gene Therapy Biomarkers

Advanced biomarker technologies can strengthen therapy development, monitoring and evaluation by providing measurable indicators of biological activity and treatment response. This webinar highlights:

  • Liquid biopsy tools for assessing biological activity and treatment response
  • RCA-based mutation detection for sensitive and precise analysis
  • Biomarker strategies that accelerate research and improve biological insights

Learn More

full-rule-line-padding-black

FAQs

What's the difference between biomarker discovery and biomarker validation, and why do both matter?

Biomarker discovery involves identifying biological signals linked to diseases, treatments or outcomes, often through multi-omics, imaging or advanced research. Validation confirms a biomarker's reliability, reproducibility and clinical value across larger datasets and populations. Both are crucial: discovery provides insights, validation builds evidence for decision-making, research, patient stratification and clinical use.

What role does AI play in biomarker discovery?

AI helps researchers analyze large, complex biomarker data by identifying patterns and potential candidates, accelerating interpretation, supporting predictive models and guiding decision-making. Success relies on high-quality, well-structured data.

How can automation improve biomarker studies?

Automation improves biomarker studies by reducing manual errors, increasing reproducibility and enabling high-throughput testing. Standardized workflows lead to more consistent results across operators and labs, supporting large-scale programs. Automation also accelerates timelines, reduces workload and helps organizations advance biomarkers from discovery to clinical use with greater confidence.

What is involved in an end-to-end biomarker and multi-omics workflow, from sample prep to data connectivity?

An end-to-end biomarker workflow involves sample collection, data generation, analysis and clinical translation. It includes standardized sample prep, multi-omics, imaging, automated workflows and integrated data systems. Linking data from different sources unifies environments, reduces fragmentation, improves consistency and speeds up insights.

Why are multi-omics workflows important?

Multi-omics workflows combine genomics, transcriptomics, proteomics, metabolomics and imaging to better understand disease biology. This integration helps researchers find mechanisms missed by single methods, identify reliable biomarkers and improve drug discovery. As organizations seek to enhance patient stratification, generate treatment insights and accelerate precision medicine, multi-omics is increasingly essential.

full-rule-line-padding-black

Find Out More

TTAE

TTAE

546005641

TTAE

add

Talk to an Expert

https://lifesciences.danaher.com

https://lifesciences.danaher.com/us/en/connect/thank-you.html